Kaye KS, et al. - This study incorporated an examination of the efficacy and adverse events of meropenem-vaborbactam in complicated urinary tract infection (UTI), including acute pyelonephritis. Meropenem-vaborbactam vs piperacillin-tazobactam gave rise to a composite outcome of complete resolution or improvement of symptoms along with microbial eradication that met the noninferiority criterion among subjects with complicated UTI, with the inclusion of acute pyelonephritis and growth of a baseline pathogen.